Pharmacologic transgene control systems for gene therapy

✍ Scribed by Wilfried Weber; Martin Fussenegger

• Publisher: John Wiley and Sons
• Year: 2006
• Tongue: English
• Weight: 355 KB
• Volume: 8
• Category: Article
• ISSN: 1099-498X
• DOI: 10.1002/jgm.903

✦ Synopsis

Abstract

Pharmacologic transgene‐expression dosing is considered essential for future gene therapy scenarios. Genetic interventions require precise transcription or translation fine‐tuning of therapeutic transgenes to enable their titration into the therapeutic window, to adapt them to daily changing dosing regimes of the patient, to integrate them seamlessly into the patient's transcriptome orchestra, and to terminate their expression after successful therapy. In recent years, decisive progress has been achieved in designing high‐precision trigger‐inducible mammalian transgene control modalities responsive to clinically licensed and inert heterologous molecules or to endogenous physiologic signals. Availability of a portfolio of compatible transcription control systems has enabled assembly of higher‐order control circuitries providing simultaneous or independent control of several transgenes and the design of (semi‐)synthetic gene networks, which emulate digital expression switches, regulatory transcription cascades, epigenetic expression imprinting, and cellular transcription memories. This review provides an overview of cutting‐edge developments in transgene control systems, of the design of synthetic gene networks, and of the delivery of such systems for the prototype treatment of prominent human disease phenotypes. Copyright © 2006 John Wiley & Sons, Ltd.